Funds · 13F holdings

Sector Gamma As

13F holdings for Q2 2026 · OSLO, Q8 · filed August 12, 2026

Sector Gamma As reported $461M in 13F securities across 40 holdings for Q2 2026, in a Form 13F filed August 12, 2026. The largest positions were BMY (9.1%), MRK (6.0%), Medtronic PLC SHS (6.0%). Reported value rose 8.9% from the quarter before. It opened 7 new positions, added to 19, trimmed 11 and sold out of 9.

13F value Q2 2026
$461M
Holdings
40
Change vs prior quarter
+8.9%
Rank by 13F value
#4,089

Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.

Top holdings

StockValueWeightSharesChange in sharesMove
BMY Bristol-Myers Squibb Company$41.8M9.1%726,115-12.3%Trimmed
MRK Merck & Company Inc.$27.9M6.0%217,008-16.6%Trimmed
Medtronic PLC SHS$27.6M6.0%352,437+25.6%Added
PFE Pfizer Inc.$24.2M5.2%1,004,215-8.0%Trimmed
INCY Incyte Corp.$19.4M4.2%170,753-14.8%Trimmed
ELV Elevance Health Inc.$17.2M3.7%44,499+1.2%Added
BMRN BioMarin Pharmaceutical Inc.$16.9M3.7%294,918+22.9%Added
TMO Thermo Fisher Scientific Inc$16.8M3.7%33,584NewNew
CVS CVS Health Corporation$16.1M3.5%155,337+14.8%Added
IQV IQVIA Holdings Inc.$15.1M3.3%77,944+93.7%Added
IONS Ionis Pharmaceuticals Inc.$15.0M3.3%189,468+11.8%Added
BDX Becton Dickinson and Company$14.1M3.1%93,168+12.8%Added
ABT Abbott Laboratories$13.4M2.9%147,444+68.4%Added
GEHC GE HealthCare Technologies Inc.$13.3M2.9%207,863+64.4%Added
ZBH Zimmer Biomet Holdings Inc.$12.3M2.7%142,307-8.7%Trimmed
BIIB Biogen Inc.$11.7M2.5%54,163-39.9%Trimmed
Qiagen NV Ord Shares$11.2M2.4%287,640+77.1%Added
CNC Centene Corporation$10.4M2.3%162,4050%Unchanged
REGN Regeneron Pharmaceuticals Inc.$9.8M2.1%15,780NewNew
BIO Bio-Rad Laboratories Inc.$9.8M2.1%33,350+40.4%Added
CAH Cardinal Health Inc.$9.7M2.1%40,689-25.9%Trimmed
AMGN Amgen Inc.$9.5M2.1%26,281-44.3%Trimmed
BRKR Bruker Corporation$9.2M2.0%152,352-40.0%Trimmed
AVTR Avantor Inc.$9.0M1.9%906,088+30.3%Added
PTCT PTC Therapeutics Inc.$8.2M1.8%100,000+33.3%Added

Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $461M in share positions; options and bonds count in the 13F value but not here.

Biggest buys in Q2 2026

  1. TMO Thermo Fisher Scientific Inc New+$16.8M
  2. REGN Regeneron Pharmaceuticals Inc. New+$9.8M
  3. IQV IQVIA Holdings Inc. Added+$7.3M
  4. Ascendis Pharma A/S New+$5.7M
  5. Medtronic PLC SHS Added+$5.6M
  6. ABT Abbott Laboratories Added+$5.4M
  7. GEHC GE HealthCare Technologies Inc. Added+$5.2M
  8. BSX Boston Scientific Corporation New+$5.2M
  9. Qiagen NV Ord Shares Added+$4.9M
  10. TVTX Travere Therapeutics Inc. New+$4.5M

Biggest sells in Q2 2026

  1. UNH UnitedHealth Group Incorporated Sold out-$9.9M
  2. BIIB Biogen Inc. Trimmed-$7.8M
  3. AMGN Amgen Inc. Trimmed-$7.6M
  4. GILD Gilead Sciences Inc. Sold out-$7.4M
  5. LNTH Lantheus Holdings Inc. Sold out-$7.1M
  6. BRKR Bruker Corporation Trimmed-$6.1M
  7. BMY Bristol-Myers Squibb Company Trimmed-$5.9M
  8. MRK Merck & Company Inc. Trimmed-$5.6M
  9. Ascendis Pharma A/S Sponsored Sold out-$4.9M
  10. CAH Cardinal Health Inc. Trimmed-$3.4M

The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 7 new, 19 added, 11 trimmed, 9 sold out.

Sector mix

13F value by quarter

Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
Reported 13F value: Q1 2024 $355M, Q2 2024 $268M, Q3 2024 $330M, Q4 2024 $291M, Q1 2025 $312M, Q2 2025 $306M, Q3 2025 $403M, Q4 2025 $439M, Q1 2026 $423M, Q2 2026 $461M.

More holdings

StockValueWeightSharesChange in sharesMove
LH Labcorp Holdings Inc.$7.3M1.6%26,019+36.8%Added
DXCM DexCom Inc.$6.9M1.5%102,122+82.0%Added
Ascendis Pharma A/S$5.7M1.2%21,305NewNew
EW Edwards Lifesciences Corporation$5.5M1.2%60,4020%Unchanged
SNDX Syndax Pharmaceuticals Inc.$5.3M1.1%241,739-15.5%Trimmed
BSX Boston Scientific Corporation$5.2M1.1%121,128NewNew
KURA Kura Oncology Inc.$4.8M1.0%433,012+5.1%Added
TVTX Travere Therapeutics Inc.$4.5M1.0%80,000NewNew
Crinetics Pharmaceuticals Inc Com$4.3M0.9%114,628+21.7%Added
TNDM Tandem Diabetes Care Inc.$4.0M0.9%267,0910%Unchanged
IOVA Iovance Biotherapeutics Inc.$4.0M0.9%968,466+7.6%Added
CYTK Cytokinetics Incorporated$3.8M0.8%45,000NewNew
OGN Organon & Co.$3.7M0.8%270,781-28.0%Trimmed
ARDX Ardelyx Inc.$3.5M0.8%686,844+33.1%Added
NTLA Intellia Therapeutics Inc.$3.1M0.7%185,177NewNew

Questions about Sector Gamma As

What does Sector Gamma As own?
In its Form 13F for Q2 2026, Sector Gamma As reported 40 holdings worth $461M. The five largest were BMY, MRK, Medtronic PLC SHS, PFE, INCY.
What did Sector Gamma As buy and sell in Q2 2026?
Sector Gamma As opened 7 new positions, added to 19, trimmed 11 and sold out of 9 compared with the quarter before.
When did Sector Gamma As file its latest 13F?
Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 12, 2026.

From Form 13F filed by Sector Gamma As (SEC CIK 0001475373) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds · Get this as JSON